Press Releases – BeiGene LTD

Press Releases

Nov 22, 2022
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022    read more...
Nov 17, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)    read more...
Nov 15, 2022
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care    read more...
Nov 10, 2022
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers    read more...
Nov 09, 2022
BeiGene Reports Third Quarter 2022 Financial Results    read more...
Nov 04, 2022
BeiGene to Present at Upcoming Investor Conferences    read more...
Nov 03, 2022
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting    read more...
Nov 02, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma    read more...
Oct 26, 2022
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America    read more...
Oct 14, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL    read more...
Oct 12, 2022
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial    read more...
Sep 19, 2022
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment    read more...
Sep 19, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma    read more...
Sep 10, 2022
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer    read more...
Sep 07, 2022
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference    read more...
Aug 23, 2022
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China    read more...
Aug 15, 2022
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care    read more...
Aug 09, 2022
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer    read more...
Aug 04, 2022
BeiGene Reports Second Quarter 2022 Financial Results    read more...
Jul 14, 2022
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC    read more...